Study: Patient voices must guide decisions on new T1D therapies
A new Breakthrough T1D-funded study finds that people with T1D and their caregivers are largely willing to try advanced new T1D therapies.
Hy-Vee and Breakthrough T1D: Changing lives
Hy-Vee has been a trusted partner of Breakthrough T1D since 1988, raising nearly $20 million through corporate and store events.
A new Breakthrough T1D publication is paving the way for beta cell replacement therapies
Breakthrough T1D’s newest publication outlines a roadmap for beta cell replacement therapies for type 1 diabetes.
New publication alert: Engineered islets are making insulin and avoiding immune detection in first person treated
Hypoimmune (HIP) islets are making insulin, without immunosuppressants, in the first person treated with type 1 diabetes.
“We are our own solution:” A T1D parent’s reflection on progress
Moira McCarthy reflects on the transformative impact of automated insulin delivery systems, and how the T1D community made it possible.
Who is at risk for type 1 diabetes?
Although its exact causes are unknown, researchers have uncovered type 1 diabetes risk factors that increase a person's likelihood of developing the condition.
Everything you need to know about ADA 2025
Check out Breakthrough T1D's ADA 2025 coverage of cutting-edge T1D updates in cures, improving lives, and clinical adoption.
Can continuous glucose monitors benefit people without type 1 diabetes?
Continuous glucose monitors have been transformative for daily type 1 diabetes management. Can they benefit people without diabetes?
ADA 2025 Recap: Medical Affairs
Medical Affairs (+Research and Advocacy) Breakthrough T1D’s Medical Affairs program is bridging the gap between access to and adoption of therapies, treatments, drugs, and devices for T1D. To accomplish this goal, the Medical Affairs team is working on healthcare provider (HCP) education, development of clinical care guidelines, and clinical trial education and awareness. Breakthrough T1D’s […]
ADA 2025 Recap: Cures
Breakthrough T1D was in Chicago, IL for ADA 2025. Here we report on the latest advancements in cures for type 1 diabetes.
